Incyte研发总裁Pablo J. Cagnoni博士强调，此次合作将加速其管线中重要靶点的小分子药物研发。Genesis创始人兼首席执行官Evan Feinberg博士表示，期待将其GEMS人工智能平台与Incyte的药物开发专业知识相结合，推进重症治疗方案的发展。

Incyte and Genesis will leverage Genesis’ GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough ...

US biopharma Incyte and privately-held AI-focused biotech Genesis Therapeutics have entered into a strategic collaboration ...

“Partnering with Genesis Therapeutics presents a unique opportunity to leverage their AI technologies to accelerate the ...

Incyte and Genesis Therapeutics have entered a strategic partnership aimed at the research, discovery and development of new ...

Incyte (INCY) and Genesis Therapeutics announced that the companies have entered into a strategic collaboration focused on the research, ...

Incyte and Genesis Therapeutics have agreed to discover and optimize at least two initial small molecule compounds through Genesis’s AI platform, Genesis Exploration of Molecular Space (GEMS).

GEMS (Genesis Exploration of Molecular Space), the partnership will pursue the discovery and optimization of small molecule compounds for the collaboration targets. Incyte is granted exclusive ...

Incyte and Genesis will leverage Genesis’ GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough small molecule therapeutics against Incyte-selected targets Incyte ...

The deal between Incyte and Genesis has a potential value of more than $900 million. Incyte Corp. is making a big bet on artificial intelligence with a new drug discovery partnership potentially ...